1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Relationship between in vivo 3T carotid plaque components and recent ipsilateral thromboembolic symptoms for 50 patients with mild/moderate carotid stenosis measured by contrast-enhanced MR angiography
Variable Symptomatic (n = 6) Asymptomatic (n = 44) OR (95% CI) PValue AUC
Plaque burden 
    % wall volume 61.0 ± 5.8 56.1 ± 9.2 1.93 (0.70–5.31)^a .204 0.689
    % stenosis on MRA 50.8 ± 6.9 55.5 ± 9.7 0.61 (0.25–1.46)^a .265 0.339
    Ulceration on MRA 50% 36% 1.75 (0.32–9.72) .661 0.568
Prevalence plaque components 
    Fibrous cap thin/ruptured 100% 39% n/a (2.13-infinity)^b .006^c 0.807
    Lipid-rich necrotic core 100% 43% n/a (1.77-infinity)^b .022^c 0.784
    Hemorrhage 67% 25% 6.00 (0.96–37.4) .055 0.708
    Calcifications 67% 84% 0.38 (0.06–2.48) .311 0.413
% Volume of plaque components 
    Lipid-rich necrotic core 18.5 ± 12.2 6.6 ± 11.3 1.90 (1.03–3.51)^a .040 0.837
    Hemorrhage 6.9 ± 6.6 1.9 ± 5.0 3.22 (0.97–10.71)^a .056 0.750
    Calcifications 2.9 ± 3.7 4.7 ± 5.9 0.44 (0.05–4.02)^a .470 0.405
a  OR and 95% CI for a 10% increase.
b  Lower limit CI estimated by exact logistic regression analysis. “n/a” was used because OR cannot be calculated in the presence of zero cells in a 2 × 2 table.
c  Fisher exact test.